EUVIMEDEUVIMED entdecken
Crossref

Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA

Yung Hsiang Kao, David Pook, Jeremy Shapiro, Mark Frydenberg, Dinesh Sivaratnam

Journal of Nuclear Medicine Technology · 2026

DOI: 10.2967/jnmt.125.270563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, 2026. Verfasst von Yung Hsiang Kao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia; yung.kao@mh.org.au. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radioisotopes, Dipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Today's common practice of empiric activity prescription in radiopharmaceutical therapy is inconsistent with the modern philosophy of personalized medicine. We investigate the radiobiologic relationship between tumor mean absorbed dose (D mean) and progression-free survival (PFS) in 177Lu-PSMA I&T therapy guided by personalized predictive dosimetry in metastatic castration-resistant prostate cancer.

Methods

We conducted a single-center retrospective study of the first 20 patients treated with 177Lu-PSMA I&T at our institution. PFS was calculated from the day a patient was assessed by a nuclear medicine physician in the clinic until treatment cessation (due to progression or toxicity) or death. D mean was estimated by predictive dosimetry. Correlation with PFS was performed on the following baseline characteristics: age, Gleason score, Eastern Cooperative Oncology Group performance status, estimated glomerular filtration rate, prostate-specific antigen (PSA) doubling time, injected activity per treatment, D mean and D mean per gigabecquerel.

Results

Twenty patients naïve to 177Lu-PSMA were treated over a 2-y period, totaling 65 infusions. The median PSA doubling time was 1.6 mo at baseline. The median follow-up time was 8.4 mo (interquartile range [IQR], 4.6-14.5 mo). Each patient received 3 ± 1 treatments (range, 1-5), with a mean injected activity of 7.74 ± 0.66 GBq per treatment. The mean injected activity for the first treatment was 7.85 ± 0.71 GBq. The median D mean for the first treatment was 23 Gy (IQR, 15-36 Gy). The median PFS was 10.6 mo for a D mean of 23 Gy or greater and was 3.1 mo for a D mean of less than 23 Gy (hazard ratio, 0.39; 95% CI, 0.22-0.68; P 0.05).

Conclusion

We found a strong direct correlation between D mean and PFS in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA in a real-world setting. We identified a D mean of 23 Gy as a possible threshold for significantly better PFS in our cohort with median PSA doubling time of 1.6 mo. Our findings support radiobiologically sound prescription based on the radiation absorbed dose by personalized predictive dosimetry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumRadioisotopesDipeptidesRadiation DosageHeterocyclic Compounds, 1-RingHumansMaleProgression-Free SurvivalNeoplasm MetastasisRetrospective StudiesAgedRadiotherapy DosageMiddle AgedAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMAabsorbed dose–responsemetastatic castration-resistant prostate cancerpredictive dosimetryprogression-free survivaltheranostics

Substanzen

LutetiumRadioisotopeslutetium (177Lu) vipivotide tetraxetanLutetium-177DipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia; yung.kao@mh.org.au.
  • Department of Medical Oncology, Cabrini Hospital, Malvern, Victoria, Australia.
  • Faculty of Medicine, Monash University, Clayton, Victoria, Australia.
  • Urology Research Department, Cabrini Hospital, Malvern, Victoria, Australia; and.
  • Department of Nuclear Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • GenesisCare, Cabrini Hospital, Malvern, Victoria, Australia.

Zitieren

APA

Kao, Y. H., Pook, D., Shapiro, J., Frydenberg, M., & Sivaratnam, D. (2026). Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.125.270563

Vancouver

Kao YH, Pook D, Shapiro J, Frydenberg M, Sivaratnam D. Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA. Journal of Nuclear Medicine Technology. 2026. doi:10.2967/jnmt.125.270563

BibTeX
@article{Kao2026,
  author = {Kao, Yung Hsiang and Pook, David and Shapiro, Jeremy and Frydenberg, Mark and Sivaratnam, Dinesh},
  title = {Correlation of Tumor Absorbed Dose with Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA},
  journal = {Journal of Nuclear Medicine Technology},
  year = {2026},
  doi = {10.2967/jnmt.125.270563}
}
Kostenlos starten →